Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RD07 cell injection
- Development stage
- Phase 1
- Modality
- Cell Therapies
- Administration
- Injection
01
Overview
RD07 cell injection is an investigational cell therapy being developed for the treatment of patients with advanced Claudin18.2 positive solid tumors. Clinical trials are underway with a single-arm, open-label, dose-increasing design, including dose escalation and dose expansion phases. The therapy is being explored for indications such as stomach adenocarcinoma, esophagus adenocarcinoma, and pancreatic cancer.
- Other names
- RD07 cellRD-07 cellRD 07 cellRD07细胞
02
Targets
XCR1 (X-C motif chemokine receptor 1)Claudin 18.2IL7R (Interleukin-7 Receptor)
Beyond the preview
Go deeper on RD07 cell injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RD07 cell injection.